References
- La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;20:124–40.
- Fares FA, Suganuma N, Nishimori K, et al. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. PNAS 1992;89:4304–8.
- De Greef R, Zandvliet AS, de Haan AF, et al. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther 2010;88:79–87.
- Popovic-Todorovic B, Loft A, Bredkjaeer HE, et al. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Hum Reprod 2003;18:2275–82.
- Oliviennes F, Howles CM, Borini A, et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2009;18:195–204.
- Devroey P, Boostanfar R, Koper NP, et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063–72.
- Obruca A, Schenk M, Tews G, et al. Corifollitropin alfa for ovarian stimulation in IVF: randomized trial in lower-body-weight women. Reprod Biomed Online 2010;21:66–76.
- Mahmoud Youssef MA, van Wely M, Aboulfoultouh I, et al. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril 2012;97:876–85.
- Polyzos NP, De Vos M, Humaidan P, et al. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril 2013;99:422–6.
- Polyzos NP, De Vos M, Corona R, et al. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod 2013;28:1254–60.
- La Marca A, D'Ippolito G. Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction. Reprod Biomed Online 2014;28:183–90.
- Yates AP, Rustamov O, Roberts SA, et al. Anti-mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26:2353–62.
- Bentzen JG, Forman JL, Johannsen TH, et al. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013;98:1602–11.
- Norman RJ, Zegers-Hochschild F, Salle BS, et al. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 2011;26:2200–8.
- Boostanfar R, Shapiro B, Levy M, et al. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril 2015;104:94–103.
- Tarlatzis BC, Griesinger G, Leader A, et al. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 2012;24:410–19.
- Polyzos NP, Tournaye H, Guzman L, et al. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2013;100:430–7.
- Arce JC, La Marca A, Mirner Klein B, et al. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;99:1644–53.
- Kolibianakis EM, Venetis CA, Bosdou JK, et al. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Hum Reprod 2015;30:432–40.
- Wikland M, Bergh C, Borg K, et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001;16:1676–81.
- Out HJ, Rutherford A, Fleming R, et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004;19:90–5.